CXA-201 + Levofloxacin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Complicated Urinary Tract Infection

Conditions

Complicated Urinary Tract Infection, Pyelonephritis

Trial Timeline

Jun 20, 2011 → Sep 4, 2013

NCT ID

NCT01345929

About CXA-201 + Levofloxacin

CXA-201 + Levofloxacin is a phase 3 stage product being developed by Merck for Complicated Urinary Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01345929. Target conditions include Complicated Urinary Tract Infection, Pyelonephritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01345929	Phase 3	Completed	Jun 20, 2011	Sep 4, 2013	Complicated Urinary Tract Infection

Competing Products

20 competing products in Complicated Urinary Tract Infection

See all competitors

Product	Company	Stage	Hype Score
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo	Jiangsu Hengrui Medicine	Phase 3	77
HRS -8427 + Imipenem and Cilastatin Sodium	Jiangsu Hengrui Medicine	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
Vancomycin + Daptomycin + Semi-Synthetic Penicillin	Merck	Approved	85
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
CXA-101 + Ceftazidime	Merck	Phase 2	52
Ceftolozane/Tazobactam + Meropenem	Merck	Phase 2	52
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
Daptomycin + Vancomycin	Merck	Approved	85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
KLU156 + Coartem	Novartis	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	52

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved